ReportWire

Tag: Medical Cannabis

  • High Tide Inc. (HITI): Among High Growth Canadian Stocks to Buy

    [ad_1]

    We recently published an article titled 9 High Growth Canadian Stocks to Buy. 

    High Tide Inc. (NASDAQ:HITI), founded in 2009, is Canada’s largest cannabis retailer and the country’s highest revenue-generating cannabis company, with an annualized revenue run rate of approximately $600 million.

    High Tide Inc. (HITI): Among High Growth Canadian Stocks to Buy

    In mid-December, High Tide Inc. (NASDAQ:HITI) also began positioning itself for potential U.S. expansion as the White House moved toward rescheduling cannabis and announced plans to test Medicare coverage for CBD products. Management has indicated it is exploring licensing the Canna Cabana brand in the United States and developing CBD offerings aligned with Medicare frameworks, which could provide an early pathway into the world’s largest cannabis-related market without immediate exposure to full federal legalization risks. To support this next phase of growth, the company reengaged an investor relations firm to strengthen market communications as it targets expanded opportunities across cannabis and CBD in both domestic and international markets.

    The company further strengthened its leadership as Canada’s largest cannabis retailer by expanding its Canna Cabana footprint to 218 stores, deepening both its national market share and its rapidly growing loyalty base. This scale has helped propel the company to a $600 million annualized revenue run rate while supporting improved profitability, highlighting the operating leverage embedded in its retail-first, membership-driven model. At the same time, High Tide Inc. (NASDAQ:HITI) took a meaningful step toward international diversification by entering Germany’s medical cannabis market, signaling ambitions that extend well beyond its Canadian core.

    While we acknowledge the potential of HITI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 13 Best Dividend Kings to Buy in 2026 and 14 Best Mid Cap Dividend Aristocrat Stocks to Buy Now

    Disclosure: None.

    [ad_2]

    Source link

  • NE Medical Cannabis Commission Approves New Rules Restricting Patient Access

    [ad_1]

    Members of the Nebraska Medical Cannabis Commission have approved additional regulations limiting patients’ ability to access medical cannabis products. The passage of the new rules, which await final approval from Republican Gov. Jim Pillen, mark the latest effort by regulators to undermine the state’s 2024 voter-approved medical cannabis access law, which Nebraskans supported by a margin of more than 2 to 1.

    Previous rules approved by the Commission in July repeal patients’ access to botanical cannabis, limit the total number of state-licensed dispensaries to no more than twelve, and require physicians to specify which cannabis formulation, potency, and dose is appropriate for each individual patient. On Tuesday, commissioners approved additional regulations limiting the total number of state-licensed cultivators to no more than four and requiring doctors to undergo ten hours of medical education training prior to discussing medical cannabis therapy with their patients, among other changes.

    Crista Eggers, Executive Director of Nebraskans for Medical Marijuana, the advocacy group that led the successful 2024 ballot effort, criticized the Commission’s decisions.

    “By approving rules that pile on new barriers and unlawfully restrict forms of cannabis, they are dismantling what the people demanded at the ballot box,” Eggers said in a statement. “This is a direct assault on patients, families and the democratic process itself. Nebraskans voted for access to medicine. Instead, the commission delivered defiance, obstruction and betrayal.”

    In public testimony provided to the Commission, NORML’s Deputy Director Paul Armentano similarly described regulators’ actions as “a slap in the face to Nebraska voters.”

    The Commission is required to begin licensing medical cannabis establishments by October 1, 2025. However, state Attorney General Mike Hilgers has threatened to sue regulators if they move forward with licensing. “The sale of marijuana — medicinal or otherwise — is not lawful, and therefore, is unconstitutional,” Hilgers opined in April. “So as the attorney general, my job is to enforce the Constitution.”

    NORML’s Deputy Director said that elected officials in Republican-led states have become increasingly hostile to voter-approved laws, despite their bipartisan public support. Lawmakers in Mississippi and South Dakota successfully sued to nullify election results in those states legalizing cannabis. In Texas, Republican Attorney General Ken Paxton has sued several cities in order to overturn voter-initiated marijuana depenalization laws. In Ohio, GOP leadership are considering a pair of bills to significantly roll back the state’s voter-approved adult-use legalization law.

    “In a healthy democracy, those with competing visions on public policy vie for voters’ support and abide by their voting decisions. However, it is becoming clear that those who oppose marijuana policy reform would rather take voters out of the equation altogether,” Armentano said. “Whether or not one personally supports or opposes cannabis legalization, these undemocratic tactics ought to cause of deep concern.”

    Additional information is available from Nebraskans for Medical Marijuana. A summary of the Commission’s August 4th meeting is available from the Nebraska Liquor Control Commission.

    [ad_2]

    NORML

    Source link

  • Can I Pick Up My Elderly Parent’s Medical Marijuana?

    [ad_1]


    Elderly Resources

    Kenneth Bancale

    by Kenneth Bancale

    April 21, 2025 08:00 am ET
    Estimated Read Time: 7 Minutes

    A nurse standing behind a man sitting down. Medical marijuana caregiverA nurse standing behind a man sitting down. Medical marijuana caregiver

    As more states adopt medical marijuana programs, questions about caregiver rights and responsibilities become increasingly common. If you’re caring for an aging parent and want to help them manage their medical marijuana, understanding your role, rights, and limitations is essential. Let’s break down everything caregivers should know, from the initial steps to ongoing responsibilities.

     

    What is a Cannabis Caregiver?

    A cannabis caregiver is an individual authorized to assist a medical marijuana patient in obtaining and administering their medication. Caregivers play a critical role for those who cannot manage their medical cannabis needs independently, including elderly patients with mobility challenges, chronic illnesses, or cognitive impairments. Caregivers can be family members, friends, or hired professionals, and they must meet the criteria set by the state’s medical marijuana program to act in this capacity legally.

    A caregiver’s responsibilities often extend beyond simply picking up medical marijuana. They may include understanding the patient’s treatment plan, administering the medication, and monitoring its effects. This role requires a clear commitment to the patient’s well-being and a solid understanding of local laws and regulations surrounding medical cannabis.

     

    What Caregivers Need to Know About Medical Marijuana

    Medical marijuana is still subject to strict regulations and varies widely between states. Caregivers must stay informed about these regulations to ensure they remain compliant and safeguard both themselves and the patient. Here’s what caregivers should prioritize:

    Understanding State Laws

    Caregivers must familiarize themselves with their state’s medical marijuana laws, as these dictate everything from the process for obtaining caregiver status to legal possession limits and the type of cannabis products that can be used.

    Administering Cannabis Safely

    The caregiver should be well-versed in how to administer cannabis to meet the patient’s specific needs, whether through tinctures, edibles, vaporizers, or other forms.

    Recognizing Potential Side Effects

    Knowing how to identify and address potential side effects is critical. Common effects include drowsiness, dry mouth, or dizziness. Caregivers should monitor their loved ones closely and communicate openly with the recommending physician.

    Storage and Security

    The proper storage of medical marijuana ensures it stays effective and safe from misuse. Cannabis should be stored in a secure, child-proof container in a cool, dark place to maintain its potency.

     

    Should You Talk with Your Aging Parent About Medical Marijuana?

    Discussing medical marijuana with an elderly parent can be sensitive, especially if they have preconceived notions about cannabis. However, many older adults are open to learning about new treatments that could improve their quality of life. When initiating the conversation, keep these points in mind:

    Approach with Empathy

    Understand their concerns or hesitations. Be prepared to share educational resources and reputable studies to ease their worries.

    Focus on Health Benefits

    Emphasize the potential advantages, such as pain relief, improved sleep, and reduced anxiety. Tailor the conversation to their specific health conditions.

    Involve Healthcare Providers

    Encourage them to speak with their doctor or a cannabis-trained medical professional to provide an expert perspective on how cannabis might benefit them.

     

    How to Become a Medical Marijuana Caregiver

    Becoming a medical marijuana caregiver involves a series of steps that vary by state but generally include these common elements:

    Consult State Regulations

    Every state has its own set of rules regarding caregiver eligibility. Typically, caregivers must be at least 18 or 21 years old and pass a background check. Check your state’s Department of Health or medical marijuana program website for specific guidelines.

    Complete the Application Process

    You’ll need to apply either online or through a paper submission. The process often requires providing personal information, a background check, and documentation that proves your connection to the patient.

    Receive Your Caregiver ID Card

    Once approved, caregivers receive an identification card that grants them the legal right to pick up and handle medical marijuana on behalf of the patient. This card must be renewed according to the schedule set by state law, typically every one to two years.


    When is the Right Time for a Patient to Use Medical Marijuana?

    Determining the right time to introduce medical marijuana into a patient’s treatment plan requires a well-considered approach that balances potential benefits with individual needs and health conditions. While medical cannabis has gained recognition for its therapeutic benefits, it is essential to assess when its use becomes an appropriate option. Here are some key factors to consider:

    Severity of Symptoms

    Medical cannabis is often considered when a patient experiences significant pain, discomfort, or other symptoms that traditional treatments have failed to address adequately. For conditions like chronic pain, severe arthritis, or neuropathy, medical marijuana may offer effective relief when other treatments have not.

    Doctor’s Recommendation

    A physician’s advice is essential for deciding when to start using medical marijuana. Medical professionals can evaluate the patient’s health profile, current medications, and potential benefits of cannabis to ensure it is a safe option. They can also provide guidance on appropriate dosages and methods of consumption tailored to the patient’s condition.

    Quality of Life Considerations

    Medical cannabis can make a significant difference in managing issues such as chronic pain, anxiety, or sleep disturbances, especially for elderly patients. If these issues are severely impacting the patient’s day-to-day life, medical marijuana might be a suitable addition to their treatment plan to improve their comfort and overall well-being.

    Sensitivity and Tolerance

    Older adults often have a different response to medications due to changes in metabolism and liver function. Starting with a low dose and gradually increasing as needed under medical supervision helps minimize side effects and allows the patient to become accustomed to cannabis treatment safely.

    Monitoring and Adjustments

    Introducing medical marijuana should include ongoing monitoring to assess its effectiveness and any side effects. Regular follow-up visits with a healthcare provider can help determine if dosage adjustments are necessary or if a different strain or method of consumption would be more beneficial.

    By considering these factors and working closely with healthcare professionals, patients and caregivers can make informed decisions about incorporating medical marijuana into a comprehensive treatment plan. For those seeking assistance, Veriheal connects individuals with experienced medical experts who can guide them through the process and help tailor a cannabis treatment plan that meets their specific needs.

     

    Frequently Asked Questions

    Can a caregiver pick up medical marijuana in Florida?

    Yes, a caregiver registered with the Florida Medical Marijuana Use Registry (OMMU) can legally purchase and pick up medical marijuana for their designated patient.

    Can someone else pick up my medical marijuana in Florida?

    Only registered caregivers can pick up medical marijuana for a patient. If you are not officially designated as a caregiver, you cannot legally purchase or transport cannabis for someone else.

    Does marijuana have special risks for the elderly?

    While medical marijuana can offer significant benefits to elderly patients, such as pain relief and improved sleep, it also comes with potential risks like dizziness or cognitive impairment. Consulting a medical professional to monitor dosage and response is essential.

    How to Buy Medical Marijuana in Pennsylvania as a Caregiver

    Caregivers in Pennsylvania must register through the state’s Medical Marijuana Program, complete a background check, and receive approval. Once certified, they can purchase medical marijuana for their patient at state-approved dispensaries.

    How To Become a Medical Marijuana Caregiver in Ohio

    In Ohio, caregivers must be registered through the Ohio Medical Marijuana Control Program (OMMCP). This process involves submitting an application, passing a background check, and linking your registration to your designated patient’s account.

    What is a Marijuana Caregiver Allowed to Do?

    A marijuana caregiver can legally obtain, transport, and administer medical marijuana to their designated patient. They must comply with all state laws regarding possession limits and product types.

    [ad_2]

    Source link

  • Texas Expands Access to Medical Cannabis

    [ad_1]

    Republican Gov. Greg Abbott has signed legislation into law expanding patients’ access to state-qualified medical cannabis products.

    House Bill 46 opens the Texas Compassionate Use Program to include those suffering from chronic pain, Crohn’s disease, traumatic brain injury, and other newly eligible conditions. It also expands the variety of cannabis formulations that patients may possess and significantly increases the total number of state-licensed dispensaries that can operate in the state from three to a total of fifteen.

    Under the revised law, which takes effect on September 1, 2025, patients are permitted to vaporize but not smoke cannabis. Medical cannabis products may not exceed 10 mgs of THC per dosing unit. Physicians may authorize up to a 90-day supply of medical cannabis to qualifying patients.

    According to 2025 data provided by the Texas Department of Safety, over 116,000 patients are active participants in the Compassionate Use Program. Lawmakers initially enacted legislation establishing the Compassionate Use Program in 2015 and expanded it in 2021. Following these latest expansions, NORML classifies Texas as the 40th medical cannabis state.

    Additional information about the Texas Compassionate Use Program is available from the Texas Department of Public Safety.

    [ad_2]

    NORML

    Source link

  • ND Gov Signs Bill Allowing Medical Cannabis Edibles

    [ad_1]

    Republican Gov. Kelly Armstrong has signed legislation into law regulating the manufacturing and dispensing of cannabis-infused edible products to state-qualified patients.

    House Bill 1203 legalizes patients’ access to “cannabinoid edible products.” The law defines these products as “soft or hard lozenges in a geometric square shape into which a cannabinoid concentrate or the dried leaves or flowers of the plant of the genus cannabis is incorporated.” It limits the THC content in edible products to no more than 5 milligrams per serving and 50 milligrams per package.

    Patients are currently limited to the use of botanical cannabis and/or tinctures, capsules, or topical patches.

    Approximately 10,000 North Dakotans are registered in the state’s medical cannabis access program, which voters approved in 2016.

    Patients prefer different methods of cannabis ingestion based on their own particular needs. Those seeking rapid relief typically prefer inhaling cannabis, which provides a rapid onset of effects. By contrast, cannabinoids consumed in the form of edibles possess delayed onset but tend to have longer-lasting effects.

    Additional information is available from the NORML document, Marijuana: A Primer.

    [ad_2]

    NORML

    Source link

  • Nebraska AG & US Senator Urge Lawmakers To Ignore Medical Marijuana Legalization Vote

    [ad_1]

    Nebraska’s Attorney General and former Governor are urging state lawmakers to halt efforts to adopt a pair of citizen-initiated measures regulating the possession, use, and production of medical cannabis. Some 70 percent of Nebraska voters approved the measures on election day.

    Writing in an op-ed, AG Mike Hilgers and former Governor (now US Senator) Pete Ricketts called on lawmakers to ignore the voters’ will. “The legislature has no duty to act now,” they wrote. “In fact, there are plenty of reasons to not act at all.”

    The duo opined that cannabis is “harmful, easily abused, and is not safe to consume even under medical supervision.” Ricketts, a longtime opponent of marijuana policy reform, has previously alleged: “If you legalize marijuana, you’re gonna kill your kids. That’s what the data shows from around the country.”

    During public hearings yesterday, a representative from the AG’s office warned that the state would consider filing a lawsuit if regulators moved forward with licensing medical cannabis providers, arguing that such actions are inconsistent with federal law. Opponents of the law have already filed a pair of lawsuits seeking to nullify the election outcome.

    On Monday, lawmakers also heard testimony regarding legislation, LB 483, repealing patients’ access to botanical cannabis. NORML’s Deputy Director Paul Armentano provided testimony against the bill, stating: “Elections have consequences. Nebraskans have made it clear that they want patients to have regulated access to botanical cannabis. Lawmakers must respect their vote.”

    He added: “LB 483 is undemocratic; it is also bad public policy. … Many patients seeking rapid relief of symptoms such as pain, nausea, or spasticity will suffer by having their access limited solely to cannabis pills and other oral formulations,” which are far slower to take effect.

    In total, more than 300 witnesses testified against the bill.

    Lawmakers on Monday also deliberated over separate bills providing further clarity for regulating medical cannabis access. Those efforts were supported by initiative proponents Nebraskans for Medical Marijuana, who held a rally at the state capitol yesterday morning during which they criticized the former Governor’s efforts.

    “The individuals who are continuing to be opposed are absolutely disregarding the fact that 71 percent of people in this state support safe and regulated medical cannabis,” said Campaign Manager Crista Eggers. “And I would ask them to take a look at any state that has legalized medical cannabis and I’d like them to see that their arguments hold no weight.”

    Ultimately, lawmakers did not take votes yesterday on any of the marijuana-related bills.

    NORML’s Armentano warned that elected officials’ efforts in Nebraska to undermine voters’ decisions is consistent with Republican-led efforts in several other states, including Ohio, where Senate lawmakers recently voted in favor of GOP-backed legislation rescinding much of the state’s voter-approved legalization law and recriminalizing many marijuana-related activities. Separate legislation introduced earlier this year in South Dakota that sought to repeal the state’s voter-approved medical cannabis law failed by a single vote.

    “In a healthy democracy, those with competing visions on public policy vie for voters’ support and abide by their voting decisions. However, it is becoming clear that those who oppose marijuana policy reform would rather take voters out of the equation altogether,” Armentano said. “Whether or not one personally supports or opposes cannabis legalization, these cynical and undemocratic tactics ought to be a cause of deep concern.”

    A state-by-state guide to pending marijuana legislation is available from NORML’s Take Action Center.

    [ad_2]

    NORML

    Source link

  • Patients Less Likely To Have Suicidal Thoughts Following Medical Cannabis Use

    [ad_1]

    Patients prescribed cannabis-based medicinal products (CBMPs) report decreases in the prevalence and intensity of suicidal thoughts, according to observational data published in the journal Archives of Suicide Research.

    British investigators assessed rates of suicidal ideation in a cohort of patients authorized to use botanical cannabis or oil extracts. (British physicians are permitted to prescribe cannabis-based medicinal products to patients who are unresponsive to conventional medications.)

    Researchers reported, “Three months after commencing treatment, there was a reduction in both the percentage of the sample reporting suicidal ideation and the mean severity of suicidal ideation. … Twelve-month follow-up indicated a substantial reduction in depressed mood with this reduction being more pronounced in those reporting SI [suicidal ideation at baseline.]”

    The study’s authors concluded: “To the best of our knowledge, this is the first observational study of CBMPs to report on rates of suicidal ideation. … The current findings suggest CBMPs may be effective in reducing suicidal ideation, as well as other facets of health and well-being … while also suggesting that the presence of suicidal ideation should not be used as a reason to exclude an individual from CBMPs treatment.”

    Epidemiological data has previously suggested that cannabis may reduce incidences of severe depression and suicidal thoughts in those with post-traumatic stress.

    Commenting on the study’s findings, NORML’s Deputy Director Paul Armentano said: “Numerous studies find that medical cannabis significantly improves patients’ health-related quality of life. Therefore, it is not unexpected that many of these patients would also report improvements in their mood and overall outlook following their use of medical cannabis products.”

    An abstract of the study, “Suicidal ideation in medicinal cannabis patients: A 12-month prospective study,” appears on PubMed.

    [ad_2]

    NORML

    Source link

  • Compassion Center Joins Coalition for Patient Rights in Urging DEA Hearing to Deschedule Cannabis, Protect Patient Rights and Take Action at Dec.2nd Deschedule Not Reschedule Rally

    Compassion Center Joins Coalition for Patient Rights in Urging DEA Hearing to Deschedule Cannabis, Protect Patient Rights and Take Action at Dec.2nd Deschedule Not Reschedule Rally

    [ad_1]

    Compassion Center, along with Coalition For Patient Rights (CPR) and allied organizations, calls on the DEA to fully deschedule cannabis, not reschedule it to CSA Schedule III. The move seeks to preserve patient rights to home-grown medicine, ensure affordable access, and protect small businesses. Compassion Center and CPR will be joining a unified rally of the people, taking place on December 2nd at the DEA Museum, demanding fair reforms on cannabis laws for patients nationwide. Join CPR In Supporting Compassionate Cannabis Reform!


    Online, October 24, 2024 (Newswire.com)
    –
    Compassion Center, a pioneering leader in integrative and alternative healthcare, mental health and medical cannabis advocacy, announces its solidarity with the Coalition For Patient Rights (CPR), United Empowerment Party and Nicholas Barreto, Atlas Alchemy LLC and The Key, Dopeass Glass and Jack Long, Elune Solutions,Farmer Tom Organics and Farmer Tom Lauerman, Medical Cannalyst Consulting Group LLC (MCCG), Integrative Providers Association (IPA), the Stormy Ray Cardholders’ Foundation (SRCF) and Cannalogix, and other allied organizations in urging the United States Drug Enforcement Administration (DEA) to fully DESCHEDULE cannabis from the Controlled Substances Act (CSA) NOT RESCHEDULE. This joint effort seeks to empower and protect patients and patients’ rights, and their medical providers’ licenses, particularly in states where medical marijuana is legally established and accessible, and further prevent harm to vulnerable communities under any reclassification to CSA Schedule III.

    FACT: 70% of the U.S. constituency are in favor of descheduling and are against rescheduling. With over 43K comments, to the DEA Scheduling Proposal, the people have not only spoken out about rescheduling, but have taken affirmative action against schedule III and want total descheduling of marijuana (cannabis). This is the most comments in history for any proposal ever- according to the federal register. Coalition For Patient Rights (CPR) encourages the federal government and our lawmakers to take notice, and listen to the widespread voice and will of The People: Vox Populi.

    Patients, caregivers and their families are encouraged to take an hour out of their day and get involved by contacting each of their state legislators and congressional representatives to voice their continued support for this effort, and then to donate directly to CPR and its patients’ rights campaign via Compassion Center, scanning the attached QR code or visiting the CPR website at: https://coalitionforpatientrights.org/donate/

    While many businesses can donate directly to CPR and apply that donation towards their tax liabilities, individual contributions to CPR via the Compassion Center are considered tax deductible to the extent of an individual’s tax circumstances and liability because Compassion Center is a 501(c)(3) charity.

    The DEA’s recent consideration, and redirection in Rescheduling cannabis to Schedule III has raised significant concerns within the medical cannabis community, and rightly so, too. While this move may appear to alleviate some barriers for patients and producers alike- like opening up doors to insurance billing and reimbursements for patients and/or alleviating banking restrictions for dispensaries and/or producers- it would, however, directly impose new, stringent regulations that would cripple patients’ ability to grow their own medicine and severely impact their current supply chains. The CSA Schedule III classification introduces severely heightened oversight with supervision, and tracking of the various ingredients used to produce cannabis, disproportionately infringing upon patient rights and civil liberties while simultaneously affecting the dispensaries, producers and processors, and the very patients who rely on the plant for relief so the intended benefits will be lost in the red tape that is used to hold it together.

    “We simply cannot afford to marginalize and disadvantage patients any further by restricting their legal access to their specific home-grown cannabis cultivars, nor by making it harder for their producers and their local dispensaries to continue serving the community,” said Julie Monteiro, RN, BSK, President of Compassion Center and Integrative Providers Association (IPA). “A CSA Schedule III classification will only burden our patients more, many of whom are considered indigent, with overreaching restrictions, while leaving taxpayers in a difficult position as these patients exhaust all their financial resources and state support through systemic suffering.”

    Patients, particularly those in medically underserved and economically disadvantaged communities, have found home cultivation to be a lifeline in managing their chronic health conditions. Some of those patients have developed an entire routine around healing through cultivation and connecting with their plants. A move to Schedule III would make home growing of cannabis illegal, forcing these patients to rely exclusively on state licensed dispensaries, and the products that those dispensaries may have on hand. CPR feels that this is asking for trouble, especially with the traditions of the cannabis industry focusing on what is making the most profit and not necessarily on what makes the most impact on symptoms. Dispensaries are currently strained by disproportionately leaning burdens where they are expected to simultaneously compete with other dispensaries and the illicit market, while navigating ever-changing state laws and regulations. Producers themselves would face extensive oversight and additional costs to produce and market their produce, resulting in diminished access to affordable cannabis, ultimately harming those who need it most.

    Compassion Center stands united with the Coalition For Patient Rights (CPR) in advocating for the full Descheduling of cannabis to ensure equitable access for all patients, maintaining their right to grow their own whole-plant medicine, and protecting the small businesses that serve as pillars of the medical cannabis industry. Descheduling cannabis is the only real way to truly eliminate the unjust and excessive regulations that have historically and disproportionately criminalized a plant with proven therapeutic benefits.

    “We are at a crossroads,” says James B. “J.B.” Creel, PgM, an administrator and registered lobbyist for the Compassion Center and the Integrative Providers Association (IPA). “Descheduling the cannabis plant presents an opportunity for our lawmakers to realign public policy with the needs of our patients and mother nature, and the cannabis industry in general, particularly in states that have led the way in cannabis reform. Anything less will just push patients further into hardship, harming small businesses, and placing unnecessary burdens on hardworking taxpayers, all while strengthening the illicit market.”

    The Compassion Center and its coalition partners urge the DEA to prioritize patient rights and public health while balancing liberty and freedom with economic fairness by descheduling cannabis, creating a framework that supports the freedom and wellbeing of those who rely on it most.

    Call To Action:

    December 2nd Deschedule Not Reschedule Rally: Join CPR, Compassion Center and our Allies on December 2nd, 2024 across the street from the DEA Hearing at the DEA Museum, 700 Army Navy Dr, Arlington, VA, 22202. Starting at 8 AM with assembly beginning at 7:30 AM, for what forecasters believe will be the most historic cannabis hearing ever on rescheduling from Schedule I to Schedule III under the Controlled Substances Act (CSA). We are demanding the full Descheduling, however, Not Rescheduling to ensure equal access and address the historical injustices of the failed War on Drugs. Prohibition has led to discrimination in rental housing, healthcare, mental health, family law, criminal justice and other legal systems, denying the many millions of Americans who use medical cannabis access to its well-documented therapeutic and proven medical benefits, despite minimal risks for addiction and/or adverse effects on health. Rally with Us during the DEA Hearing to Reschedule Cannabis. United organizations are in support of FULLY DESCHEDULING CANNABIS AND NOT RESCHEDULING.

    For more information on the December 2nd Rally, visit: https://www.DescheduleNotReschedule.info

    For more information on Coalition For Patient Rights, visit: https://www.MyCPR.us

    Donate to CPR: Volunteer your time or contribute cash in support of the DEA Hearing Delegation, visit: https://coalitionforpatientrights.org/donate/

    For more information on Compassion Center, and its integrative medical cannabis clinic and the various state medical cannabis program registrations, visit: https://compassion-center.net

    For information on the December 2nd Rally Organizers, please reach out directly to: Nick Baretto nicholas@deschedulenotreschedule.info and United Empowerment Party – Sephida Artis-Mills Sephida@unitedempowermentparty.org

    For more information on Compassion Center and its patient advocacy efforts, please visit: https://www.Compassion-Center.org or call 1-844-THC-COMPASSION.

    About Compassion Center
    Compassion Center is a pioneering leader in integrative healthcare and medical cannabis advocacy since 2001, serving patients in Oregon and 18 other states. The organization is dedicated to creating equitable access to medical cannabis, integrative and alternative healthcare and mental health care solutions, particularly for underserved, marginalized, and economically disadvantaged populations.

    Tags: #DescheduleNotReshedule #JustKnow #EducationistheKey #medicalmarijuana #voxpopuli #endprohibition #warondrugs #decriminalizenature #FreetheLeaf #CoalitionForPatientRights #CompassionCenter #BetheChangeYouWishToSee #wemustgrow

    Contact Information

    Sophaur One
    Director of Communications
    sophaur.one@compassion-center.org
    844-842-2667 Ext 1

    James Garvey
    CIFR Director of Collaborative Programs
    james.garvey@compassion-center.org
    844-842-COMPASSION Ext 1

    Related Video

    https://www.youtube.com/watch?v=ZLqqFFqolQY

    SOURCE: Compassion Center

    Source: Compassion Center

    Related Media

    [ad_2]

    Source link

  • Coalition for Patient Rights (CPR) Urges Immediate Medical Cannabis Law Reform in Nevada with Broad Support from Integrative Healthcare

    Coalition for Patient Rights (CPR) Urges Immediate Medical Cannabis Law Reform in Nevada with Broad Support from Integrative Healthcare

    [ad_1]


    LAS VEGAS, NV, September 25, 2024 (Newswire.com)
    –
    Compassion Center celebrates and champions the Coalition for Patient Rights (CPR) in leading the charge for urgent reforms in Nevada’s medical cannabis laws, advocating for reduced fees, patient cultivation rights, and an overhaul of outdated DUID laws. Join CPR in protecting patient access, promoting fair legislation, and ensuring the safe use of natural, organic cannabis for qualifying patients across the state. Get involved by attending monthly meetings or supporting CPR’s Washington D.C. delegation.

    The Compassion Center celebrates and champions the Coalition for Patient Rights (CPR) in urgently calling for reform of Nevada’s medical cannabis laws to protect patient access to safe and affordable medicine, and supports CPR’s Washington D.C. delegation in speaking up on behalf of patient rights. In light of growing concerns surrounding the current regulatory framework, the upcoming DEA rescheduling hearing, and the ongoing lack of understanding about medical cannabis, CPR is advocating for legislation that reduces fees and eliminates barriers to access. Our goal is to ensure that patients’ safety and rights are always protected, while providing law enforcement and regulators with clear, actionable guidelines.

    As medical cannabis continues to be recognized as a vital tool in managing a range of chronic conditions, qualifying patients in Nevada face unnecessary financial and procedural hurdles. CPR is urging lawmakers to take swift action to reduce registration fees, and even eliminate the fees altogether for disabled veterans and patients with permanent disabilities, while eliminating the current pre-application qualifications, streamlining patient access, and further eliminating the obstacles that disproportionately affect low-income and vulnerable populations.

    Central to this reform is the protection of a patient’s right to grow their own cannabis at home, free from exposure to harmful chemicals and pesticides, plant growth regulators (additives) and irradiation. CPR supports legislation that allows patients to cultivate natural, organic cannabis without the burden of taxation, ensuring they can safely manage their own treatment without any unnecessary interference, undue burdens on their privacy and liberty, without an excessive cost.

    Additionally, CPR advocates for a complete overhaul of Nevada’s pro se DUID laws, which are currently preventing medical cannabis patients from legally operating vehicles, boats, or aircraft while using cannabis to alleviate their conditions, making pharmaceuticals the only option for a professional or those supporting a family, which we all know can lead to harmful damage from side-effects. The current law is overly broad and does not account for varying levels of patient tolerance or experience, unfairly penalizing patients who rely on cannabis for chronic relief. CPR supports replacing these outdated laws with proven techniques to identify actual impairment, backed by police officer-worn body camera footage to ensure fairness and transparency.

    “With the DEA’s move to hold a hearing on rescheduling cannabis to a CSA schedule III, CPR believes the time has come for Nevada to modernize its approach to medical cannabis and the Driving Under the Influence of Drugs (DUID) laws regarding medical cannabis patients,” said Jeff Krajnak, CPR President and President of Pardon Me, Please. “Our laws should protect the patients who rely on this medicine, not punish them for seeking natural relief. Reforming access, protecting home cultivation, and replacing outdated DUI laws with science-backed measures will ensure that patients can live healthier, safer lives without fear of legal repercussions”, said Mr. Jason Greninger, CPR Director of Legislative Advocacy.”

    CPR is dedicated to collaborating with legislators, healthcare providers, and patient advocates to ensure that Nevada’s medical cannabis laws align with the needs and rights of its patients. We invite you to attend one of our monthly meetings, held on the last Wednesday of each month, or to consider donating to support a delegation that will testify at the upcoming DEA hearing in Washington D.C. on December 2nd, 2024.

    “While we acknowledge the consideration to reschedule cannabis to a Schedule III substance under the Controlled Substances Act (CSA) will open up many doors for insurance billing and inpatient integration, we hope to see the plant restored to its original status in the updated U.S. Pharmacopeia as a plant-based medicine under the Generally Recognized As Safe (GRAS) designation” Said Nurse Julie Monteiro, RN, BSK, Senior Vice President of Patient Education. “Additionally, it is critical to prioritize patients, their rights, and the accessibility and affordability of cannabis as the DEA moves forward with rescheduling.” Said James B. Creel, PgM, Board Secretary-Treasurer of Compassion Center, and Patient Advocate representing Coalition For Patient Rights (CPR) as a Research Fellow of Compassion Center’s Center for Incubation & Findings Research (CIFR).

    For more information or to get involved by volunteering or donating to send our delegation to Washington, D.C., please visit CPR at: https://coalitionforpatientrights.org/donate/

    To attend a Monthly CPR Town Hall Meeting, speak on a particular subject or just vent about the high cost of healthcare, please visit: https://coalitionforpatientrights.org/nevada-rsvp/ and a link/ ticket will be sent directly to you so you can attend. It is vital for you to let your voice be heard. We hold both in-person and online meetings regularly to ensure the voice of the people is heard.

    To be part of the next meeting, please email Vicki Higgins, Executive Vice President of Legislative Action at: Vicki.Higgins@MyCPR.us to obtain a personal invitation and directions or a link to the meeting. While some meetings are held in person at any one or more NV libraries, community centers and offices, CPR often conducts online-only meetings to ensure that the entire community has unfiltered access and the ability to get involved in the conversation.

    Contact Information

    James Garvey
    CIFR Director of Collaborative Programs
    james.garvey@compassion-center.org
    844-842-COMPASSION Ext 1

    Vicki Higgins
    Executive Vice President: Legislative Action
    vicki.higgins@mycpr.us
    844-842-8687 Ext 1

    Related Files

    CPR Flyer VOX Populi

    Related Video

    https://www.youtube.com/watch?v=ZLqqFFqolQY

    SOURCE: Coalition for Patient Rights

    Source: Compassion Center

    Related Media

    [ad_2]

    Source link

  • Nebraska Voters To Decide on Medical Cannabis Access

    Nebraska Voters To Decide on Medical Cannabis Access

    [ad_1]

    Nebraska voters will decide this Election Day on a pair of citizen-initiated ballot measures regulating medical cannabis access to authorized patients.

    State regulators last week affirmed that advocates Nebraskans for Medical Marijuana had gathered the requisite number of signatures to place the measures before voters.

    The two measures are complementary. The first permits qualified patients to possess and use cannabis. The second measure regulates the production and distribution of cannabis to those authorized patients. Advocates had to frame the issue as two separate ballot questions in order to not run afoul of the state’s ‘single subject’ rule. In 2020, the state Supreme Court invalidated a similar stand-alone measure for addressing issues that it deemed were “not naturally and necessarily connected to the [initiative’s] primary purpose.” A 2022 effort failed to obtain sufficient signatures to qualify for the ballot.

    “States have a proven track record of safely and effectively regulating medical marijuana,” NORML’s Deputy Director Paul Armentano said. “After November, Nebraskans will no longer be forced to choose between their medicine or their freedom.”

    Thirty-eight states, the District of Columbia, and several US territories regulate medical cannabis products. Statewide polling indicates that between 70 percent and 80 percent of Nebraskans support legalizing medical marijuana access.

    Nebraska is one of at least four states where cannabis-related initiatives will appear on November’s ballot. Voters in Florida, North Dakota, and South Dakota, who also will be deciding on adult-use legalization measures this fall.

    In Texas, voters in the cities of Bastrop (population 11,200), Dallas (population: 1.3 million), and Lockhart (population 15,000) will decide on municipal ballot measures prohibiting local law enforcement from making low-level marijuana-related arrests.

    Additional Election 2024 coverage is available from NORML.

    [ad_2]

    NORML

    Source link

  • D.A.R.E. Officer of the Year Discusses Relative Using Medical Cannabis for Cancer | High Times

    D.A.R.E. Officer of the Year Discusses Relative Using Medical Cannabis for Cancer | High Times

    [ad_1]

    The Drug Abuse Resistance Education, aka D.A.R.E., has been teaching kids about substance abuse since 1983 with a mission of delivering science and evidence-based curricula. Recently, a D.A.R.E. documentary published by Channel 5 with Andrew Callaghan on April 12 spoke with numerous individuals regarding the D.A.R.E. program and discussed the failure of the War on Drugs. Callaghan attended D.A.R.E.’s annual conference, which was held in Las Vegas, Nevada last July. An estimated 500 attendees were present for D.A.R.E. officer training.

    Part of the conference included presenting awards for 2023 D.A.R.E. Student of the Year and 2023 D.A.R.E. Officer of the Year Mark Gilmore, from Kosciusko, Mississippi. Gilmore commented on his ability as a D.A.R.E. officer to apprehend any students who possess any amount of drugs, which includes even the smallest amount of weed.

    D.A.R.E.’s 2022 Officer of the Year, Alex Mendoza of the Irvine Police Department spoke with Callaghan about shifting D.A.R.E.’s approach to drug prevention deterring kids from using drugs. “For me, it’s really about educating the youth that are out there,” Mendoza said. “To give them the tools necessary to navigate whatever pain that they’re going through. I think that if you don’t have that self-love for yourself and that resiliency, then you’re gonna go to that external source, whatever that might be.”

    Callaghan asked, “Do you feel the same way about alcohol?” to which Mendoza replied, “Absolutely. I mean, alcohol is a gateway drug.” Callaghan then asked Mendoza if he drinks alcohol, and Mendoza confirmed that he does so rarely, or “maybe once or twice within a month period of time.” He gave an example, stating that he recently had an alcoholic drink at his daughter’s wedding during a toast.

    Callaghan addressed this issue in the documentary, citing the validity of calling alcohol a gateway drug. He asked Mendoza if he felt cannabis could be treated in the same way as alcohol. “You know, there’s so many things about marijuana that go far beyond, I guess, really our understanding, right?” said Mendoza. “From a lot of the statistics that are out there, obviously, they say that it can be more dangerous than tobacco products.”

    However, he did note that there are many instances where cannabis is being used to help patients to deal with the symptoms of their condition. “I think the problem that you run into is that you have the people that truly legitimately have a need and a purpose behind it and will use it to help them navigate their pain,” said Mendoza. “My brother-in-law recently passed away of cancer, and he didn’t want to go with any type of prescription medication. He wanted something natural and he resulted to using THC to deal with his pain. And it helped him. He passed away, but it helped him navigate that, right? And then you have, unfortunately, people that will use that as an excuse to try to use that product for recreational purposes.”

    D.A.R.E. President and CEO Francisco Pegueros, who formerly worked for the Los Angeles Police department, concluded the conference with a speech. In a one-on-one interview, Callaghan mentioned that people being critical of the War on Drugs, Pegueros said “Well, there was some evidence that certain governmental agencies were involved in a lot of activity that were kind of contrary to the whole concept of the war on drugs,” Pegueros said. Callaghan called the “CIA giving crack to Freeway Ricky Ross,” or how the federal government was supplying Ross with cocaine for illegal sales. “It’s an unfortunate part of our history. But evidently, it’s reality,” Pegueros said.

    The documentary also interviewed one individual named Hailey, who was the only protester outside of last year’s D.A.R.E. conference last year. “We don’t try to outlaw sex. We don’t try to outlaw driving. We don’t try to outlaw guns,” Hailey stated. “We don’t try to outlaw all these things that come with risk but can be easily have these safety measures put in place, much like we do with pharmaceuticals.”

    Callaghan briefly spoke with Bill Russel, also known as RETRO BILL, who has spoken to kids across the country for more than 25 years in partnership with D.A.R.E. to warn kids about how drugs, including cannabis, are harmful and dangerous.

    The documentary stated that the D.A.R.E. program cost American taxpayers up to $750 million per year in the 1990s, up until a 1998 University of Michigan study showed that drug use continued to rise between 1992-1995, despite the nationwide prevalence of D.A.R.E.

    It also reviewed the rise of the War on Drugs through actions from former presidents Richard Nixon and later, Ronald Reagan. Former President Bill Clinton signed the Violent Crime Control and Law Enforcement Act in 1994, and D.A.R.E. lost its federal funding in 1998.

    [ad_2]

    Nicole Potter

    Source link

  • A Renewed Call for Research: Study on Medical Efficacy of Cannabis for Patients Treated for Depression – Cannabis Business Executive – Cannabis and Marijuana industry news

    A Renewed Call for Research: Study on Medical Efficacy of Cannabis for Patients Treated for Depression – Cannabis Business Executive – Cannabis and Marijuana industry news

    [ad_1]





    A Renewed Call for Research: Study on Medical Efficacy of Cannabis for Patients Treated for Depression – Cannabis Business Executive – Cannabis and Marijuana industry news





























    [ad_2]

    Julian Wichmann

    Source link

  • Study: U.S. Medical Cannabis Laws Increase Patient’s Mental Health

    Study: U.S. Medical Cannabis Laws Increase Patient’s Mental Health

    [ad_1]

    Researchers from the University of Basel in Switzerland recently published a study on April 2 to analyze how medical cannabis legalization in the U.S. has affected the country and its patients’ well-being.

    Entitled “Medical marijuana laws and mental health in the United States,” researchers wanted to determine the effects of medical cannabis policies on patients over time. “The consequences of legal access to medical marijuana for individuals’ well-being are controversially assessed,” researchers wrote. “We contribute to the discussion by evaluating the impact of the introduction of medical marijuana laws across U.S. states on self-reported mental health considering different motives for cannabis consumption.”

    Researchers analyzed the responses of 7.9 million people who participated in phone surveys between 1993-2018. This information was collected through the Behavioral Risk Factor Surveillance System, which focuses on data collection regarding “mental well-being.” In addition to this, researchers also utilized data collected by the National Survey on Drug Use and Health.

    Participants were placed in specific groups, such as those who were “highly likely to abstain from using marijuana, to use marijuana as a recreational drug, or to use it for medical reasons” in order to determine the overall affect of medical cannabis legalization on their mental health. Additionally, researchers took into account the use of cannabis specifically for overall chronic pain.

    Mental health was measured by asking participants to self-assess themselves by recording how many days they encountered mental health problems during the month prior to the assessment.

    Ultimately, researchers found that medical cannabis legalization had no effect on either recreational consumers or youth. “We find weak evidence of positive effects on mental health due to the liberalisation of medical marijuana for the U.S. population overall,” researchers wrote in their conclusion. “While the estimated overall reduction in poor mental health days is not statistically significant, the result still implies an absence of evidence for the critical perspectives that highlight the risk of aggravated mental health problems due to MML [medical marijuana laws] introductions.”

    “Easier access improves the mental health of individuals who use marijuana for medical reasons,” stated a University of Basel press article. “The same applies to people who are very likely to suffer from pain. The study authors estimate that these two groups spend 0.3 days less per month in poor mental health due to the change in the law.”

    Professor Alois Stutzer summarized these findings in his own statement as well. “Overall, our results show that medical cannabis legislation in the USA benefits the people it is intended for without harming other groups,” Stutzer said. He explained that recreational cannabis consumers aren’t worse off after legalization, either, and ultimately there is “a clear relationship between liberalization and mental well-being.”

    Both the U.S. and Switzerland both share a federal government structure. While Stutzer calls the most recent study an “experimental article” because it can help pave the way toward more studies that analyze Switzerland’s future cannabis industry.

    The most recent study only extended to data collected prior to 2018, so it would be interesting to see a future study analyze even more recent data that accompanies the many other states that have legalized medical and/or adult-use cannabis within the past five years.

    Switzerland has been conducting isolated cannabis pilot programs to analyze consumer trends, sales patterns, and more. Recently at the end of March, the first data connected to one of these programs was released.

    The ZüriCan study includes 1,928 people who have been approved to purchase cannabis for the study (a total of 2,100 individuals can participate). The newest data shared that of current participants, 80.7% are men, 18% are women, and 1% are nonbinary people. The demographic disparity was not a surprise, however, as researchers expected there to be a vast difference in gender-related consumers.

    Additionally, researchers found that participants between the ages of 28-32 represented the highest percentage among all age groups (the average age of consumers is currently 35 years old). “Participation in the study seems to be particularly attractive for people who consume frequently,” researchers wrote. “However, people who only use cannabis a few times a month also take part in the study. This will allow us to compare people with different consumption habits in our study.”

    The program data also showed that 6,500 sales have been made so far, with approximately 309 pounds of cannabis sold (individual packs were available only in five gram amounts).

    Tobias Viegener, the head of marketing Cannavigia, a company that is working directly with the Swiss Federal Office on Public Health, told Forbes about the significance of this early data. “The initial data from the ‘ZüriCan’ pilot, published this month, reveals promising insights into the regulated cannabis market’s functionality and its acceptance among participants,” Viegener said. “This level of engagement indicates a positive reception and an effective distribution system, setting a solid foundation for informing future cannabis policy and regulation.”

    [ad_2]

    Nicole Potter

    Source link

  • Australian Endometriosis Patients Find Relief Through MMJ Despite Cost Barriers | High Times

    Australian Endometriosis Patients Find Relief Through MMJ Despite Cost Barriers | High Times

    [ad_1]

    Using cannabis for pain relief is nothing new. Across the U.S., most states include chronic pain as a qualifying condition for medical cannabis.

    Looking broader, individuals around the globe are already embracing cannabis for these pain-relieving qualities alongside the additional benefits it may offer. While we’re still learning exactly how cannabis can work to treat symptoms and provide relief for specific conditions, many are taking matters into their own hands with promising results — and these trends could very well help to shape further research and policy.

    A recent survey published in the journal Obstetrics & Gynecology took a closer look at symptom management pertaining to cannabis and endometriosis, finding that patients often turn to cannabis to alleviate their symptoms despite ongoing barriers to access.

    Cannabis Use Among Endometriosis Patients

    Endometriosis is a condition where tissue similar to the lining of the uterus grows outside of the uterus, generally resulting in severe pelvic pain and inflammation. The tissue acts in the same way as the lining inside the uterus, thickening, breaking down and bleeding with each menstrual cycle. Endometriosis involving the ovaries can also result in cysts, causing surrounding tissue irritation and formation of scar tissue.

    Endometriosis can start at the time of a person’s first menstrual period and last until menopause. We still don’t know what causes endometriosis, there is no way to prevent it and there is no cure. However, there are a number of treatments to help ease the related symptoms. Some opt for surgery to remove lesions, while many embrace hormonal intrauterine devices, birth control methods, opioid-based pain medications and more for ongoing relief.

    That said, we can safely add cannabis to the list of modern-day treatments given its prevalence of use.

    In the survey, Australian researchers examined the perspectives of 192 people with a history of cannabis use and endometriosis. Noting it as a “very expensive disease, with substantive out of pocket costs for pain and symptom management,” researchers reference cost and accessibility to cannabis-based medicinal products (CMBPs) as a primary focus of the survey. They also cite the lack of information surrounding ideal products, modes of administration and efficacy in current research.

    Researchers gathered data through an online survey of Australian and New Zealand residents, via social media and community-based advocacy platform Cannareviews.co. Respondents included those using either illicit cannabis or legal CMBPs prescribed by a doctor to manage endometriosis and chronic pelvic pain-related symptoms. However, the published report only includes data from Australian respondents. 

    The survey found that THC-dominant CBMPs are most commonly prescribed to Australians with endometriosis, noting multi-product use as a common trend with most people reporting the use of at least two products. For those with only one prescription (23%), it was almost always a THC-dominant product. 

    Most respondents (59.4%) said they used cannabis recreationally and for endometriosis symptom management, though many exclusively used cannabis to manage symptoms (40.1%).

    Patients reported improvements in common endometriosis symptoms through the use of legal CBMPs, specifically sleep (68.9%), chronic pelvic pain (44.5%), nausea (47.9%), anxiety/depression (45.4%) and menstrual pain (38.7%). 

    They also reported a reduction in the use of opioids, hormonal treatments, non-steroidal inflammatory drugs, neuroleptics and illicit cannabis. 

    Oils and flower were the most common product types, illicit or legal.

    Examining Cost and Access to Cannabis Medicines

    The results also pointed to legal, THC-dominant cannabis medications being more expensive than illicit “equivalents” and that the extra cost for legal access often led to people underdosing (76.1%) or resorting to illicit cannabis to “bridge the gap” and easen cost burdens (42.9%).

    Researchers note that relying upon illicit cannabis products can lead to inadequate symptom management, using products that have not been tested for safety and quality and of course associated legal ramifications.

    Nearly all (96.3%) respondents said that their cost burden would be substantially reduced if CBMPs were a Pharmaceutical Benefits Scheme (PBS) listed and subsidized product. 

    The bulk of respondents said they would consider moving insurers if they found out their private health insurance would not reimburse the cost of cannabis medicine as well — 60.9% said maybe, depending on other factors; 20.3% said yes, so long as the premium was the same price or less; 11.7% said yes, even if the premium was higher; only 7% said no.

    Researchers said that patients’ willingness to switch insurers based on this variable “speaks to the pivotal nature of cost concerns (and perceived effectiveness) relating to affordable access to cannabinoids.” Additionally, they state that the results suggest a need for a greater response from insurers in the country.

    “Given the lack of well-tolerated alternatives for medical management of endometriosis, this is an equity issue that urgently needs addressing,” they add.

    Limitations and Looking Ahead

    Researchers note that self-reported nature of cost, diagnosis and product consumption as a limitation. They also cited the potential for their recruitment methods — through social media and Cannareviews’ patient base — to produce recall and selection bias, as participants may have either had more severe impacts to quality of life or a more positive experience with illicit or medicinal cannabis than the broader population.

    Still, the data affirms that many are already finding relief and relying on cannabis treatments for endometriosis, highlighting the need for better access.

    “Given major issues with symptom management and the self-reported reductions in pain and other symptoms, improving access to medicinal cannabis for this population is important and timely,” authors conclude. “Reductions in cost of both product and consultations, as well as coverage by insurance are areas which need addressing.”

    [ad_2]

    Keegan Williams

    Source link

  • Study: Vaporizing CBD/THC Cannabis Blend Effective for Sustained Migraine Relief | High Times

    Study: Vaporizing CBD/THC Cannabis Blend Effective for Sustained Migraine Relief | High Times

    [ad_1]

    It’s estimated that at least 39 million Americans live with migraines, though the number is likely higher due to lack of diagnosis or proper treatment. And those who experience migraines are well aware of how debilitating they can be, especially those who experience migraines on a consistent basis.

    Cannabis is already known to be beneficial for those who suffer from migraines, as it appears as a qualifying condition for a number of state medical programs. But of course, we’re still catching up on research surrounding cannabis as a whole, and there’s a lot we’re continuing to learn about cannabis and how it can work to treat specific conditions like migraines.

    A pilot study published by the National Library of Medicine took a closer look at the relationship between cannabis and migraines found that inhalation of flower with both CBD and THC may be key to providing migraine relief. The data has not yet been peer reviewed.

    First-of-its-Kind Study to Assess Cannabis for Migraine Relief

    Authors note the existing preclinical and retrospective studies suggesting that cannabinoids could be effective in treating migraines, though there are still no randomized clinical trials to assess efficacy.

    Additionally, they note the prevalence of acute treatments for migraines, like acetaminophen or ibuprofen, though rates of treatment optimization in this regard tend to be low with high rates of discontinuation. 

    To examine how cannabis may help to curb migraine symptoms, researchers from the University of California, San Diego (ECSD) conducted a randomized, double-blind, placebo-controlled crossover trial with herbal cannabis, the first of its kind according to the study. The trial involved 92 patients with persistent migraines.

    Participants were randomly assigned one of four cannabis chemotypes: 6% THC, 11% CBD, 6% THC and 11% CBD or a placebo. Upon each migraine attack onset, participants were instructed to open a smartphone application, which would prompt participants with questions surrounding whether or not the attack met the criteria for cannabis administration (if more than seven days had elapsed since the last administration, if it was less than four hours from headache onset, gauging the severity of pain, other symptoms associated with the migraine and that no acute treatments had been used since the attack onset). 

    So long as participants met the set criteria, the app would then instruct them to vaporize cannabis, inhaling for five seconds, holding their breath for 10 seconds and then waiting 45 seconds before repeating the process four times. The app then pushed surveys to participants at one, two, 24 and 48 hours following application to gauge efficacy.

    THC/CBD Blend Most Effective in Treating Migraines

    Ultimately, the study concluded that the vaporized cannabis containing THC and CBD was most effective in treating migraines. It also found that the THC/CBD blend was superior to the placebo when it came to relieving migraine-related photophobia, or light sensitivity, and phonophobia, sound sensitivity.

    “Vaporized 6% THC+11% CBD cannabis flower was superior to placebo for pain relief, pain freedom, and MBS [most bothersome symptom] freedom at 2 hours as well as 24-hour sustained pain freedom and sustained MBS freedom and 48-hour sustained MBS freedom,” authors reported, emphasizing that this blend was the only one to provide sustained benefit versus the placebo. 

    The study found that blends dominant in THC and CBD showed no difference from the placebo surrounding 24- or 48-hour sustained pain and MBS freedom.

    Regardless of the type of cannabis consumed, there were no serious adverse effects reported by participants. However, the THC-dominant blend provided the most euphoria, cognitive impairment and subjective highness, followed by the THC/CBD blend and then the CBD-dominant flower.

    Gaps in Research and Looking Ahead

    The study did not assess repeated administration or regular, long-term treatments, though researchers note a small body of literature that has found improvements on patient-reported outcomes when using cannabis-based medicinal products on regular, longer-term or preventative basis. 

    The study also only looked at single potencies of THC and CBD and a single THC:CBD ratio, and minor cannabinoids and terpenes were also left out of the study.

    In the study’s conclusion, researchers still cited the need for further research to include multicenter and long-term studies of benefits and risks regarding repeated use of cannabis to treat migraines.

    [ad_2]

    Keegan Williams

    Source link

  • Can Cannabinoids Help People Wean Off Opioids? | High Times

    Can Cannabinoids Help People Wean Off Opioids? | High Times

    [ad_1]

    Doctors desperately need tools to battle the opioid epidemic, and they’re turning to cannabinoids for new ways to approach the problem of opioid use disorder (OUD). Recently researchers aimed to create an open-access framework designed to help people wean off and eventually replace opioids with cannabinoids as an alternative. 

    Last August, a study provided a clinical framework for cannabinoids in the battle against the opioid epidemic. The study, entitled “An answered call for aid? Cannabinoid clinical framework for the opioid epidemic,” was published in Harm Reduction Journal.

    Researchers provided an evidence-based clinical framework for the utilization of cannabinoids to treat patients with chronic pain who are dependent on opioids, seeking alternatives, and tapering off of opioids.

    “Based on a comprehensive review of the literature and epidemiological evidence to date, cannabinoids stand to be one of the most interesting, safe, and accessible tools available to attenuate the devastation resulting from the misuse and abuse of opioid narcotics,” researchers wrote. “Considering the urgency of the opioid epidemic and broadening of cannabinoid accessibility amidst absent prescribing guidelines, the authors recommend use of this clinical framework in the contexts of both clinical research continuity and patient care.”

    Recent research has shown a role for CBD in treating cannabis use disorder, and likewise, the compound could be useful in treating OUD. Researchers are also exploring the potential of THC and acidic cannabinoids as well. Cannabis is known anecdotally for the treatment of low-to-moderate amounts of pain despite working in very different ways than opiates.

    The open-access framework includes opioid tapering recommendations that are in accordance with the CDC’s latest clinical practice guidelines for managing opioids for pain. 

    “As opioid deaths continue to be a global problem, patients are increasingly self-medicating with cannabis while researchers struggle to standardize protocols and providers feel uncomfortable recommending cannabinoids amidst absent prescribing guidelines,” researchers wrote. “If we consider cannabis as a harm reduction tool that patients are already using without medical guidance, we can realign our focus to supporting researchers and providers with a clinical framework for standardizing research and recommending cannabinoids more informatively as safe, effective, accessible tools for assisting in the management of chronic pain. To our knowledge, this is one of the first comprehensive evidence-based peer-reviewed clinical frameworks for the safe use of cannabinoid products for chronic pain and OUD.”

    The researchers acknowledged that many of their patients have already begun their own self-guided journey into pain management with cannabinoids.

    The Devastating Toll of Opioid Overdoses

    Opioids continue to wreak havoc on people in America, leading to confusion about who needs powerful opioids and who doesn’t, and overdose deaths continue a steady pace of devastation.

    According to The National Center for Health Statistics (NCHS) under the U.S. Centers for Disease Control and Prevention, drug overdose deaths rose from 2019 to 2021 with over 106,000 drug overdose deaths reported in 2021. Deaths involving synthetic opioids—primarily fentanyl and excluding methadone—continued its death march with 70,601 overdose deaths reported in 2021. Fentanyl in particular kills 150 Americans per day.

    Over-prescription of opioids could be part of the problem. A 2018 longitudinal analysis showed that prescriptions for all opioids in the U.S. fell by 14.4% when medical cannabis dispensaries opened—particularly for hydrocodone and morphine, but also for benzodiazepines, stimulants, and many other medications known to be over-prescribed and addictive. 

    In some states, opioid use disorder is a qualifying condition for the use of medical cannabis. Researchers are still learning about the efficacy of cannabinoids in animal and human trials.

    Studies on Cannabis and Opioid Abuse Vary

    Opioid addiction is a complex phenomenon, and studies vary in their results of whether or not cannabinoids are effective. One study concluded that there is “no evidence that cannabis reduces opioid misuse.”

    According to research published in the American Journal of Psychiatry, researchers instead found “no evidence” showing that cannabis may not be an effective long-term strategy for reducing opioid abuse.

    “There are claims that cannabis may help decrease opioid use or help people with opioid use disorders keep up with treatment. But it’s crucial to note those studies examine short-term impact and focus on treatment of chronic pain and pain management, rather than levels of opioid use in other contexts,” Dr Jack Wilson, the lead author of the study and a postdoctoral research fellow at The Matilda Centre for Research in Mental Health and Substance Use at the University of Sydney in Australia, said in a statement.

    “Our investigation shows that cannabis use remains common among this population, but it may not be an effective long-term strategy for reducing opioid use,” he added.

    Recent studies show the vast potential of cannabis in the fight against the opioid epidemic that continues to ravage the U.S.

    [ad_2]

    Benjamin M. Adams

    Source link

  • Study: German Patients Have ‘Greater Satisfaction’ With MMJ Than Previous Treatments | High Times

    Study: German Patients Have ‘Greater Satisfaction’ With MMJ Than Previous Treatments | High Times

    [ad_1]

    It’s no secret that cannabis can work as an alternative to other longstanding medicinal options as it pertains to curbing and treating pain and related symptoms. A number of studies have already confirmed the efficacy of cannabis and its compounds as it relates to pain management, though a new study suggests that patients believe it may be even more effective than conventional treatments.

    A recent survey of German patients published in the journal Frontiers in Medicine explored experiences with cannabis products, with more than 200 anonymous participant perspectives. As with many previous studies, patients largely reported reductions in their daily pain after starting cannabis therapy along with other benefits. 

    Notably, they reported “greater satisfaction” with cannabis, calling it “more effective” than their previous treatments.

    Exploring German Prescription Cannabis for Pain

    Researchers note that part of the intent behind the research is to explore “perspectives of patients whose experiences are not well enough known to date.” 

    Using a web-based survey of prescription cannabinoid patients, conducted between May 31, 2021 and June 2022, researchers conducted the research anonymously “to reduce treatment provider influence and stigma.” Subjects were asked to complete questionnaires regarding their cannabis therapy twice in the same session, once for the time of the survey and another for the period prior to their cannabis treatment.

    Participants were asked to rate their daily pain levels, along with questions around the details of the cannabinoid prescription process — namely any issues they ran into obtaining the medication — and their general attitudes around cannabis.

    Chronic pain was the most common diagnosis, with 72% of participants indicating that pain relief was the primary reason for their prescriptions.

    Germany is currently making waves in the global cannabis space for its pending legalization of recreational cannabis, though plant cannabis and cannabinoid treatments were legalized by prescription use in the country back in 2017. Cannabis medication is also typically only authorized when patients are unresponsive to traditional options.

    Researchers also note a study finding that the most common reason for German cannabinoid prescriptions from 2017 to 2022 was for pain.

    Patients Report MMJ Benefits for Pain Treatment and More, Despite Access Barriers

    “The results of this cross-sectional study suggest that most of the surveyed outpatients treated with prescription cannabinoids in Germany subjectively experience health benefits and symptom reduction associated with these therapies,” researchers state in their discussion.

    Across all diagnoses and symptom groups, authors report that participants shared positive effects on physical functioning, emotional states and quality of life. Additionally, they reported fewer problems around fulfilling their social roles and their pain symptoms were perceived to have a lesser impact on their daily lives. Satisfaction was rated by perceived effectiveness, side effects and overall satisfaction.

    Researchers suggest that the stress-reducing effect of cannabis drugs could be a “significant mediating factor,” in that opioids may have “more ambivalent effects on stress regulation because the kappa opioid receptor signaling pathway is activated by stress stimuli that produce both aversion and dysphoria in humans and other animal species.”

    Prior to cannabis therapy, participants generally had a neutral to slightly positive attitude toward cannabis, which shifted to “predominantly positive” during therapy. 

    Most of the problems during the prescription process didn’t originate with physicians but rather with reimbursement issues involving health insurance providers. Approximately 25% of participants with statutory health insurance coverage reported that they opted to pay out of pocket.

    “This is likely due to the current legal situation in Germany, where the prescription of cannabinoid medications is characterized by significant complexity and administrative hurdles, comparable to those encountered when prescribing off-label drugs, both for patients and practitioners,” researchers said.

    ‘Starting Points’ for Further Research

    The study notes that comparable studies, in which German patients are directly questioned about cannabinoid therapy, are rare, with most surveys only questioning physicians. Those studies similarly found that pain was the main reason for cannabis prescriptions.

    Standing apart from much of the current research in the region, researchers note risk of selection bias, in that patients may have been more willing to participate in the study due to successful treatments. They also note potential “expectation bias,” in that the high access barriers for cannabinoid therapies in Germany give many eligible patients high expectations, which could lead to a more favorable evaluation of such therapies, among other potential limitations.

    “This observational study nevertheless provides starting points for further discussion in the context of planning clinical cannabinoid trials and formulating appropriate research questions, involving the patients’ perspectives,” researchers concluded.

    [ad_2]

    Keegan Williams

    Source link

  • Study Shows Older Dogs Benefit From Hemp Oil

    Study Shows Older Dogs Benefit From Hemp Oil

    [ad_1]

    Man’s best friend shares the aches and illnesses of old age – now a study offers a little help for them

    We love and consider them family, so as they age we want to help our little loves. As they age, our dogs often suffer a decline in functioning and can get sick more often. Because there is almost nothing sadder than a dog that’s feeling sick, you can give your dog hemp seed oil full of vitamin E and vitamin A to help their immune system fight any chemicals, drugs, pesticides and toxins that your dog may pick up in its day-to-day life.

    RELATED: Fireworks And Pets, Can Marijuana Or CBD Help

    Also, medical research has given some hope to older dogs. A study from the College of Veterinary Medicine at Cornell University revealed hemp oil can help aging dogs suffering from joint pain.

    Photo by Jamie Street via Unsplash

    According to the study, a hemp-based medicine developed by ElleVet Sciences is “efficacious for pain in dogs with osteoarthritis, chronic joint pain and geriatric pain and soreness; with dramatic beneficial effects in our more geriatric patients.” The first-of-its-kind study took eight months to complete and examined how ElleVet’s soft chews metabolized and how it relieved joint pain in canines.

    RELATED: Science Says Medical Marijuana Improves Quality Of Life

    Joseph Wakshlag, associate professor of Cornell University’s College of Veterinary Medicine presented the findings of the first pharmacokinetic study and clinical trial on the use of cannabinoids to treat dogs with osteoarthritis and multi-joint pain at the Veterinary Meeting & Expo. The university partnered with ElleVet Sciences to conduct this double-blind, placebo-controlled study.

    [ad_2]

    Terry Hacienda

    Source link

  • Japan to legalise medical use of cannabis, revising stringent drug laws, but toughens ban on recreational marijuana use – Medical Marijuana Program Connection

    Japan to legalise medical use of cannabis, revising stringent drug laws, but toughens ban on recreational marijuana use – Medical Marijuana Program Connection

    [ad_1]

    Japan’s parliament has passed a bill to legalise cannabis-based medicines in a landmark revision of its stringent drug laws, while toughening its ban on recreational use of marijuana.

    The changes to Japan’s cannabis and narcotics control laws passed on Wednesday in the upper house will pave the way for the lifting of a ban on medical products derived from cannabis.

    Under the revised laws, which enter into force within a year from promulgation, cannabis and tetrahydrocannabinol (THC), a psychoactive chemical found in the plant, are designated as narcotics to be regulated.

    Cannabis-based medicines, produced with the active ingredient cannabidiol, or CBD, are already used overseas to treat various conditions such as severe epilepsy.

    What you need to know about a proposed ban on CBD products in Hong Kong

    This is a win for patient groups that have campaigned for access to these medicines.

    However, the changes amount to a tightening of Japan’s already tough cannabis policy.

    Marijuana consumption was criminalised, closing a loophole that officials partly blamed for a recent rise in cannabis-related arrests.

    Before the revisions, inhaling marijuana had been technically legal, whereas possessing it was punishable by a jail term of up to five years.

    The loophole was originally introduced to prevent farmers from being arrested for accidentally inhaling psychoactive smoke when growing hemp.

    But alarmed by the recent spike in arrests over cannabis, especially among young people including…

    Original Author Link click here to read complete story..

    [ad_2]

    MMP News Author

    Source link

  • Report: 90% of Virginia Med Patients Obtain Weed Outside of State’s Medical Market | High Times

    Report: 90% of Virginia Med Patients Obtain Weed Outside of State’s Medical Market | High Times

    [ad_1]

    It’s not uncommon for residents of states yet to enact cannabis laws to travel and obtain their weed through out-of-state dispensaries. However, one Southern state appears to be experiencing this issue when it comes to medical cannabis, even though it’s had legal, operational medical dispensaries since 2020.

    A new 78-page report released by the Virginia Cannabis Control Authority (CCA) takes a closer look at the state’s medical cannabis market, most notably finding that the state’s high prices are driving consumers to bordering states to purchase their cannabis products.

    The report is the result of a request on behalf of the CCA from earlier in 2023, to study Virginia’s medical cannabis program with a focus on patient access and “determining the necessity and feasibility of adding new licenses to the existing program.” The study involved a population survey of past-year cannabis consumers and patients, an assessment of supply based on patient experiences and a policy analysis.

    High Prices Push Virginians Out of State, Alternative Means

    “The study found that the Virginia medical cannabis program is struggling to capture patients amid evolving local policies as well as adult-use policies in bordering states, resulting in prices remaining high,” the report notes, adding that 12% of patients report traveling to obtain cannabis from other states or jurisdictions, largely Washington, D.C. and Maryland.

    According to the report, medical cannabis patients in Virginia spend more on cannabis than non-medical cannabis patients in the state. It also notes that patients in Virginia report spending an estimate of $19 per gram on average for medical cannabis flower, which is higher than the national average for medical cannabis flower — though looking at the publicly available price data, the report found that the average price of a medical gram in Virginia was closer to $14, which is still higher than average.

    By comparison, the average price per medical gram in D.C. was $8/73 in September 2023; in Maryland, adult-use cannabis is $9.27 per gram on average.

    Looking broader, 90% of patients purchased cannabis from sources other than the Virginia medical market, and the largest proportion of grams were obtained from “an unregulated, but not necessarily illicit, market.”  Additionally, 57% of medical patients obtained their cannabis by growing at home, while 65.2% of patients received cannabis from a friend or family. 

    Virginia MMJ Program’s Low Barriers, Low Participation

    Despite low barriers to patient participation, Virginia’s estimated patient enrollment encompasses 0.5% of the total state population, which authors say supports the assertion that patients can meet their need for medical cannabis elsewhere. 

    Of those past-year consumers who are not patients, 22% said they did not need to become medical patients because they already had access to cannabis.

    “Virginia’s restrictive policy framework, including limited licensing and the Health Service Area (HSA) segmentation, coupled with the widespread availability of cannabis from out-of-state markets, home cultivation, and illicit channels, has created an environment in which Pharmaceutical Processors are operating at their profit-maximizing supply quantity,” the report states. 

    “In other words, licensees may have no expectation of increased profits if they expand their supply and lower prices because substitute markets have recently taken root.”

    Solutions Needed to Sustain Virginia’s Medical Program

    The report notes that the high prices of Virginia’s medical cannabis are “likely necessary” for Pharmaceutical Processors to stay afloat due to the current state market and policies that accompany it, rather than intentionally overcharging medical patients.

    Authors also lay out five potential pathways to improve patient access to medical cannabis, with the shared objective to increase supply, lower prices and shift patient demand to regulated Pharmaceutical Processors.

    The pathways include a mix of potential options, like issuing the remaining Pharmaceutical Processor licenses in the HSA or adding limited standalone medical cultivation, manufacturing and dispensary licenses allowed to operate within any HSA while allowing Pharmaceutical Processors to expand beyond the current six-store minimum within their area.

    [ad_2]

    Keegan Williams

    Source link